Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
Background: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, cou...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-06-01
|
Series: | Prostate International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2287888215301057 |
id |
doaj-89ffd9ec557441d68bd4b87264b91822 |
---|---|
record_format |
Article |
spelling |
doaj-89ffd9ec557441d68bd4b87264b918222020-11-25T00:29:58ZengElsevierProstate International2287-88822016-06-0142545510.1016/j.prnil.2016.02.002Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillationSimon Rauch0Dominic Fong1Elisa Morra2Francesca Maines3Orazio Caffo4Gilbert Spizzo5Department of Internal Medicine, “F. Tappeiner” Hospital, Merano, ItalyDepartment of Haematology and Oncology, “F. Tappeiner” Hospital, Merano, ItalyDepartment of Cardiology, “F. Tappeiner” Hospital, Merano, ItalyDepartment of Oncology, Santa Chiara Hospital, Trento, ItalyDepartment of Oncology, Santa Chiara Hospital, Trento, ItalyDepartment of Haematology and Oncology, “F. Tappeiner” Hospital, Merano, ItalyBackground: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, could limit its use in patients with atrial fibrillation. Methods: We retrospectively reviewed the clinical records of 85 metastatic castration-resistant prostate cancer patients treated with AA at our institutions and identified six patients suffering from concomitant atrial fibrillation. Results: In these six patients, the median duration of AA treatment was 11.5 months (range 4–22 months) with a biochemical response in three patients. No significant cardiac events were observed during the treatment. Conclusion: Our data suggest that AA may be safely administered in patients with atrial fibrillation.http://www.sciencedirect.com/science/article/pii/S2287888215301057Abiraterone acetateAtrial fibrillationProstate cancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Simon Rauch Dominic Fong Elisa Morra Francesca Maines Orazio Caffo Gilbert Spizzo |
spellingShingle |
Simon Rauch Dominic Fong Elisa Morra Francesca Maines Orazio Caffo Gilbert Spizzo Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation Prostate International Abiraterone acetate Atrial fibrillation Prostate cancer |
author_facet |
Simon Rauch Dominic Fong Elisa Morra Francesca Maines Orazio Caffo Gilbert Spizzo |
author_sort |
Simon Rauch |
title |
Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation |
title_short |
Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation |
title_full |
Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation |
title_fullStr |
Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation |
title_full_unstemmed |
Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation |
title_sort |
feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation |
publisher |
Elsevier |
series |
Prostate International |
issn |
2287-8882 |
publishDate |
2016-06-01 |
description |
Background: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, could limit its use in patients with atrial fibrillation.
Methods: We retrospectively reviewed the clinical records of 85 metastatic castration-resistant prostate cancer patients treated with AA at our institutions and identified six patients suffering from concomitant atrial fibrillation.
Results: In these six patients, the median duration of AA treatment was 11.5 months (range 4–22 months) with a biochemical response in three patients. No significant cardiac events were observed during the treatment.
Conclusion: Our data suggest that AA may be safely administered in patients with atrial fibrillation. |
topic |
Abiraterone acetate Atrial fibrillation Prostate cancer |
url |
http://www.sciencedirect.com/science/article/pii/S2287888215301057 |
work_keys_str_mv |
AT simonrauch feasibilityofabirateroneacetatetreatmentinpatientswithmetastaticcastrationresistantprostatecancerandatrialfibrillation AT dominicfong feasibilityofabirateroneacetatetreatmentinpatientswithmetastaticcastrationresistantprostatecancerandatrialfibrillation AT elisamorra feasibilityofabirateroneacetatetreatmentinpatientswithmetastaticcastrationresistantprostatecancerandatrialfibrillation AT francescamaines feasibilityofabirateroneacetatetreatmentinpatientswithmetastaticcastrationresistantprostatecancerandatrialfibrillation AT oraziocaffo feasibilityofabirateroneacetatetreatmentinpatientswithmetastaticcastrationresistantprostatecancerandatrialfibrillation AT gilbertspizzo feasibilityofabirateroneacetatetreatmentinpatientswithmetastaticcastrationresistantprostatecancerandatrialfibrillation |
_version_ |
1725328709252022272 |